Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
Neurocrine Biosciences (NASDAQ: NBIX) has scheduled its second quarter 2025 financial results conference call and webcast for July 30, 2025, at 1:30 p.m. Pacific Time. The company will release its Q2 2025 financial results at 1:00 p.m. PT on the same day.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for multiple conditions including tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company maintains a diverse pipeline with several compounds in mid to late-phase clinical development.
Neurocrine Biosciences (NASDAQ: NBIX) ha programmato la conference call e la trasmissione web dei risultati finanziari del secondo trimestre 2025 per il 30 luglio 2025 alle 13:30 ora del Pacifico. L'azienda pubblicher脿 i risultati finanziari del Q2 2025 alle 13:00 PT dello stesso giorno.
Neurocrine Biosciences 猫 una societ脿 biofarmaceutica specializzata in neuroscienze con trattamenti approvati dalla FDA per diverse patologie, tra cui discinesia tardiva, corea di Huntington, iperplasia surrenalica congenita, endometriosi e fibromi uterini. L'azienda dispone di un ampio portafoglio di prodotti con diversi composti in fase clinica medio-avanzata.
Neurocrine Biosciences (NASDAQ: NBIX) ha programado su llamada y webcast para presentar los resultados financieros del segundo trimestre de 2025 el 30 de julio de 2025 a la 1:30 p.m. hora del Pac铆fico. La compa帽铆a publicar谩 sus resultados financieros del Q2 2025 a la 1:00 p.m. PT el mismo d铆a.
Neurocrine Biosciences es una empresa biofarmac茅utica enfocada en neurociencias con tratamientos aprobados por la FDA para m煤ltiples condiciones, incluyendo discinesia tard铆a, corea de Huntington, hiperplasia suprarrenal cong茅nita, endometriosis y fibromas uterinos. La compa帽铆a mantiene una cartera diversa con varios compuestos en desarrollo cl铆nico de fase media a avanzada.
Neurocrine Biosciences (NASDAQ: NBIX)電� 2025雲� 7鞗� 30鞚� 韮滍弶鞏� 響滌鞁� 鞓ろ泟 1鞁� 30攵勳棎 2025雲� 2攵勱赴 鞛 鞁れ爜 旎嵓霟办姢 旖� 氚� 鞗轨簮鞀ろ姼毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� 臧欖潃 雮� 鞓ろ泟 1鞁�(PT)鞐� 2攵勱赴 2025雲� 鞛 鞁れ爜鞚� 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
Neurocrine Biosciences電� 歆�鞐办劚 鞖措彊鞛レ暊, 項岉寘韯� 氍措弰氤�, 靹犾矞靹� 攵�鞁犼臣順曥劚歃�, 鞛愱秮雮措歃�, 鞛愱秮攴检 霌� 鞐煬 歆堩櫂鞐� 雽�頃� FDA 鞀轨澑 旃橂鞝�毳� 氤挫湢頃� 鞁犼步瓿柬暀 欷戩嫭鞚� 氚旍澊鞓れ牅鞎� 須岇偓鞛呺媹雼�. 須岇偓電� 欷戧赴鞐愳劀 頉勱赴 鞛勳儊 臧滊皽 雼硠鞐� 鞛堧姅 鞐煬 頇旐暕氍检潉 韽暔頃� 雼れ枒頃� 韺岇澊頂勲澕鞚胳潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
Neurocrine Biosciences (NASDAQ : NBIX) a programm茅 sa conf茅rence t茅l茅phonique et son webcast concernant les r茅sultats financiers du deuxi猫me trimestre 2025 pour le 30 juillet 2025 脿 13h30, heure du Pacifique. La soci茅t茅 publiera ses r茅sultats financiers du T2 2025 脿 13h00 PT le m锚me jour.
Neurocrine Biosciences est une soci茅t茅 biopharmaceutique sp茅cialis茅e en neurosciences, disposant de traitements approuv茅s par la FDA pour plusieurs affections, notamment la dyskin茅sie tardive, la chor茅e de Huntington, l'hyperplasie cong茅nitale des surr茅nales, l'endom茅triose et les fibromes ut茅rins. La soci茅t茅 poss猫de un portefeuille diversifi茅 avec plusieurs compos茅s en d茅veloppement clinique de phase interm茅diaire 脿 avanc茅e.
Neurocrine Biosciences (NASDAQ: NBIX) hat seine Telefonkonferenz und Webcast zur Bekanntgabe der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r den 30. Juli 2025 um 13:30 Uhr Pazifikzeit angesetzt. Das Unternehmen wird seine Finanzergebnisse f眉r Q2 2025 am selben Tag um 13:00 Uhr PT ver枚ffentlichen.
Neurocrine Biosciences ist ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften und verf眉gt 眉ber FDA-zugelassene Behandlungen f眉r mehrere Erkrankungen, darunter tardive Dyskinesie, Chorea Huntington, kongenitale adrenale Hyperplasie, Endometriose und Uterusmyome. Das Unternehmen verf眉gt 眉ber eine vielf盲ltige Pipeline mit mehreren Wirkstoffen in mittleren bis sp盲ten klinischen Entwicklungsphasen.
- None.
- None.
Conference Call and Webcast Scheduled for Wednesday, July 30
The schedule for the press release and conference call / webcast is as follows:
- Q2 2025 Press Release: July 30, 2025 at 1:00 p.m. PT / 4:00 p.m. ET
- Q2 2025 Conference Call: July 30, 2025 at 1:30 p.m. PT / 4:30 p.m. ET
- Domestic Dial-In Number: 800-225-9448
- International Dial-In Number: 203-518-9708
- Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at . A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit , and follow the company on , 听补苍诲 .
(*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:
SOURCE Neurocrine Biosciences, Inc.
FAQ
When is Neurocrine Biosciences (NBIX) Q2 2025 earnings call?
How can I access Neurocrine Biosciences Q2 2025 earnings call?
What treatments does Neurocrine Biosciences (NBIX) have FDA approval for?
How long will Neurocrine's Q2 2025 earnings webcast be available?
